CLOVER (CLOstridium difficile Vaccine Efficacy tRial) Study: A Phase 3, Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of <i>Clostridioides difficile</i> Infection
Curtis J. Donskey(Geriatric Research Education and Clinical Center), Nicholas Kitchin(Johns Hopkins University), Kenneth Koury(Johns Hopkins University), Mark H. Wilcox(University of Leeds), Nicola P. Klein, Stephen Lockhart(Johns Hopkins University), Kathrin U. Jansen(Pfizer (United States)), Helen Smith(Pfizer (United Kingdom)), Elizabeth Liles(Kaiser Permanente Center for Health Research), Erik R. Dubberke(Washington University in St. Louis), Warren V. Kalina(Pfizer (United States)), Salim Bouguermouh(Pfizer (United States)), Michael W. Pride(Pfizer (United States)), William C. Gruber(Pfizer (United States)), Haiying Zhang(Liaoning University of Traditional Chinese Medicine), Ruth Bailey(Johns Hopkins University), Katarzyna Szymkowiak(Nexus Clinical Research (Canada)), Jody Lawrence(Pfizer (United States)), Annaliesa S. Anderson(Pfizer (United States)), Chris Webber(Pfizer (United Kingdom)), Erik Lamberth(Pfizer (United States))
Cited by 37
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
|Clinical Infectious Diseases|2017|2.7k
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
|Nature|2020|1.6k